WYNEFCY Trademark

Trademark Overview


On Thursday, December 8, 2022, a trademark application was filed for WYNEFCY with the United States Patent and Trademark Office. The USPTO has given the WYNEFCY trademark a serial number of 97709825. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Thursday, August 1, 2024. This trademark is owned by Eli Lilly and Company. The WYNEFCY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative co...
wynefcy

General Information


Serial Number97709825
Word MarkWYNEFCY
Filing DateThursday, December 8, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateThursday, August 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 19, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 6, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, December 12, 2022NEW APPLICATION ENTERED
Friday, January 6, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 14, 2023ASSIGNED TO EXAMINER
Monday, August 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 30, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, September 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, October 19, 2023EXTENSION OF TIME TO OPPOSE RECEIVED
Sunday, January 28, 2024EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, April 9, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, August 1, 2024SOU TEAS EXTENSION RECEIVED
Thursday, August 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 1, 2024SOU EXTENSION 1 GRANTED
Thursday, August 1, 2024SOU EXTENSION 1 FILED